ADMA - ADMA BIOLOGICS, INC.

21.86
-0.470   -2.150%

Share volume: 2,617,355
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$22.33
-0.47
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
63%
Profitability 77%
Dept financing 13%
Liquidity 75%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.60%
1 Month
7.90%
3 Months
35.19%
6 Months
33.05%
1 Year
232.22%
2 Year
552.54%
Key data
Stock price
$21.86
P/E Ratio 
20.51
DAY RANGE
$21.61 - $22.35
EPS 
$0.85
52 WEEK RANGE
$6.50 - $23.64
52 WEEK CHANGE
$232.22
MARKET CAP 
4.054 B
YIELD 
N/A
SHARES OUTSTANDING 
233.083 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,361,192
AVERAGE 30 VOLUME 
$3,672,447
Company detail
CEO: Adam S. Grossman
Region: US
Website: admabiologics.com
Employees: 530
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ADMA Biologics, Inc. engages in developing, manufacturing, and marketing specialty plasma-derived biologics. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI) and ASCENIV. Nabi-HB for the. treatment of acute exposure to blood containing Hepatitis B surface antigen.

Recent news
loading